Bavarian Nordic A/S (BVNRY) Q1 2026 Earnings Call Transcript
Denmark's Bavarian Nordic raises 2026 forecast
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Bavarian Nordic A/S (BVNRY) Q4 2025 Earnings Call Transcript
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
Bavarian Nordic – Completion of Share Buy-Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Short Interest in Bavarian Nordic (OTCMKTS:BVNRY) Drops By 41.9%
Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees
Bavarian Nordic A/S (BVNRY) Q3 2025 Earnings Call Transcript
Bavarian Nordic chair Debruyne steps down after failed takeover
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Nordic Capital, Permira takeover offer for Bavarian Nordic falls through
Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
Bavarian Nordic signs EU smallpox and mpox vaccine contract for up to 8 million doses
Consortium consisting of Nordic Capital and Permira lowers the minimum acceptance condition to 66 2/3% in respect of the takeover offer to the shareholders of Bavarian Nordic
Bavarian Nordic's Largest Shareholder Stands Firm Against $3.1 Billion Private-Equity Takeover Bid
Nordic Capital-led consortium raises takeover price for Bavarian Nordic to $38.94 per share
Bavarian Nordic A/S (BVNKF) Q2 2025 Earnings Call Transcript
Bavarian Nordic beats revenue expectations, as launch of takeover bid nears
Consortium led by Nordic Capital, Permira to acquire Bavarian Nordic
Bavarian Nordic in talks with Nordic Capital and Permira on potential takeover
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country
Bavarian Nordic A/S (BVNKF) Q1 2025 Earnings Call Transcript
Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)
Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S
Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S
Bavarian Nordic Trading At Great Value Levels With Upbeat 2025 Outlook
US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
Bavarian Nordic A/S – Notice Convening Annual General Meeting
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
Bavarian Nordic A/S (BVNKF) Q4 2024 Earnings Call Transcript
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Bavarian Nordic Publishes Annual Report 2024
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
Bavarian Nordic – Completion of Share Buy-Back Program
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Bullish On Bavarian Nordic's Vaccine Portfolio And Revenue Potential In 2025
Bavarian Nordic's Mpox Moment Fades, But Diversification Shines
Bavarian Nordic A/S (BVNKF) Q3 2024 Earnings Call Transcript
Bavarian Nordic CEO says Kennedy nomination could fuel vaccine scepticism
Bavarian Nordic has $340 mln orders for its mpox, smallpox vaccine in 2025